期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 12, 期 6, 页码 344-357出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2015.38
关键词
-
类别
资金
- American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital
- National Cancer Institute of the US National Institutes of Health
- Alex's Lemonade Stand Foundation
- American Association for Cancer Research
- American Society of Haematology
- Henry Schueler 419 Foundation
- Leukemia and Lymphoma Society
- National Health and Medical Research Council (Australia)
- Pew Charitable Trusts
- Stand Up To Cancer
- St Baldrick's Foundation
Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer and an important cause of morbidity from haematological malignancies in adults. In the past several years, we have witnessed major advances in the understanding of the genetic basis of ALL. Genome-wide profiling studies, including microarray analysis and genome sequencing, have helped identify multiple key cellular pathways that are frequently mutated in ALL such as lymphoid development, tumour suppression, cytokine receptors, kinase and Ras signalling, and chromatin remodeling. These studies have characterized new subtypes of ALL, notably Philadelphia chromosome-like ALL, which is a high-risk subtype characterized by a diverse range of alterations that activate cytokine receptors or tyrosine kinases amenable to inhibition with approved tyrosine kinase inhibitors. Genomic profiling has also enabled the identification of inherited genetic variants of ALL that influence the risk of leukaemia development, and characterization of the relationship between genetic variants, clonal heterogeneity and the risk of relapse. Many of these findings are of direct clinical relevance and ongoing studies implementing clinical sequencing in leukaemia diagnosis and management have great potential to improve the outcome of patients with high-risk ALL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据